Close

Product Liability Lawyer Blog

Updated:

Abbot Labs Accused of Hiding Testosterone Replacement Therapy Dangers

AndroGel is a topical hormone marketed to men experiencing complications from low levels of natural testosterone. AndroGel was heavily promoted by Abbott Laboratories and AbbVie Inc., with the companies selling the product through testimony from retired professional athletes. Abbott Laboratories and AbbVie Inc. also provided statistics and fed positive reports…

Updated:

Major Chicken Provider Shut Down for Unsanitary Conditions

Foster Farms, a chicken processing plant in California, didn’t open re-open its doors last week after it was shut down by officials because of an alleged cockroach infestation, report NBC. Officials with the company state that they needed more time to address the problem before opening in good faith. Officials…

Updated:

Actos Bladder Cancer Bellwether Trial Begins

A federal jury is preparing to hear a bellwether case regarding the alleged cancer-causing diabetes drug Actos, manufactured by Asia’s largest drugmaker, Takeda Pharmaceuticals. The plaintiff in Terrence Allen et ux. v. Takeda Pharmaceuticals North America Inc. et al alleges damages in excess of $75,000 after he says he developed…

Updated:

Maine’s Relaxed Import Drug Law & Risk of Dangerous Drugs

Concerns regarding defective drugs in New England are heightened, following Maine’s recent passage of a law that allows residents there to import prescription drugs from overseas. The policy’s staunch critics include the Pharmaceutical Research and Manufacturer’s of America, the Maine Pharmacy Association and big-name drug manufacturers such as Pfizer and…

Updated:

Biomet Looks Ahead as Defective Hip Cases Move Forward

Biomet recently announced its financial results for the second quarter, indicating an increase in consolidated net sales and announcing the commercial launch of the company’s G7™ Acetabular System in 2014. The financial release indicated that the report contained forward looking statements and that the company’s actual results could be affected…

Updated:

Leukemia Drug Iclusig Expected to Resume Marketing Amid Safety Concerns

A new leukemia drug hit the market last year – and approval was promptly suspended by the U.S. Food and Drug Administration amid concerns that it caused the potential for life-threatening blood clots and a severe restriction of the blood vessels. The drug, known as Iclusig and ponatinib, has reportedly…

Updated:

Faulty Hip Replacements Result in $56 Million Settlement from Biomet

Biomet Inc., a medical device manufacturer based in the U.S., has agreed to pay a minimum of $56 million in order to settle a multi-district lawsuit stemming from defective metal hip replacements. Court filings in the case of In Re: Biomet M2A Magnum Hip Implant Products Liability Litigation, from the…

Contact Us